



Attorney Docket No.: 5885.204-US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Callisen et al.

Confirmation No: 1686

Serial No.: 10/019,156

Group Art Unit: 1761

Filed: December 3, 2001

Examiner: To be assigned

For: Chemically Modified Lipolytic enzyme

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)**

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 95/35381

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or

PATENT

COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED  
APR 26 2002  
TC 1700

**before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: April 17, 2002

  
\_\_\_\_\_  
Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

FORM PTO-1447  
REV. 1-90U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Atty. Docket No.

5885.204-US

Serial No.

10/019,156

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Applicant

Callisen et al.

Filing Date

December 3, 2001

Group

1761

Use several sheets if necessary.

## U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	95/35381	December 28, 1995	WO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


COPY OF PAPERS  
ORIGINALLY FILEDRECEIVED  
APR 26 2002  
TC 1700

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

